Home » Public Policy

Regulatory Affairs

Derek Gregg, Chair of BioWV and Chief Executive Officer of Vandalia Research

BIOtechNow’s Tracy Cooley discusses biotech in West Virginia – major growth areas, outlook for the future, and upcoming plans for the BIO International Convention – with Derek Gregg.

IP: Imperative for Innovation

Patent systems can provide an advantage to society by rewarding the development of new inventions, promoting the advancement of technology and protecting the investor.  Patents often are the most important, and sometimes only, asset of a biotech company. Patents and related rights must be obtained in a timely and predictable manner and the ability to enforce those patents is critical.

Massachusetts Life Sciences Center Awards $3.75 Million to Early Stage Companies

The Massachusetts Life Sciences Center, which is tasked with administering the $1 billion state's life sciences initiative, has awarded five loans to start up companies, totaling $3.75 million.

Market Watch: Revamped Website Offers Agri-Biotech Product Info

Overhauled BIOTradeStatus lets users search for the latest information on hundreds of products.

Virginia Makes Gains: Lawmakers Pass Biotech-Friendly Budget

Budget victories will help biotechnology in the Commonwealth

Senate committee marks up SBIR/STTR reauthorization
Patent Reform Passes the Senate and Moves to the House

The Patent Reform Act of 2011 would strengthen and improve our nation’s patent system, spurring innovation and job creation.

Budgets & Biotech: Congress Urged to Continue Supporting Advanced Biofuels

Industry leaders point out that biotech-enabled advanced biofuels spur job growth and reduce U.S. dependence on imported oil.

Solid Results: Survey Shows Therapeutic Discovery Project Works

The government’s Qualifying Therapeutic Discovery Project Program is doing what it was intended to do, according to a recent survey of senior executives at small biotechnology companies.

Will Your Worldview Change at the BIO International Convention?

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year’s BIO International Convention.  Created in partnership with BIO, the publication explores the diverse economic regions of the world, highlighting success stories, policy achievements, cutting-edge science and the unique challenges that lie ahead. This year’s report focuses on BRIC (Brazil, Russia, India and China) country efforts to build local biotechnology hubs. 

Biotech Beets: USDA Lets Farmers Resume Planting

Agency issues partial deregulation of Roundup Ready sugar beets while it prepares an environmental impact statement.

BioBytes: The Biotech Drug Delivery Timeline

Biotech research holds a great deal of promise for future innovation in the treatment of previously untreatable diseases. But how long does it take for a biotech therapy to come to market?

What Arguments Were Made in Genentech’s Citizen Petition on Biosimilars?

On April 8, 2004, Genentech, Inc. filed a Citizen Petition with the Food and Drug Administration (FDA), requesting that the agency refrain from (1) publishing a draft guidance document setting forth standards for so-called follow-on or "generic" biotechnology-derived products, and (2) approving an application filed under section 505(b)(2) of the Food, Drug and Cosmetic Act (FDCA) with respect to a biotechnology product that relies, directly or indirectly, on trade secret and confidential commercial data and information of an innovator.

What Legal Issues are Presented by Biosimilars?
Healing, Fueling, Feeding: How Biotechnology Is Enriching Your Life.

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

Letters, Testimony & Comments

Cell and Gene Therapy: BIO Comments on Preclinical Assessment of Investigational Cellular and Gene Therapy Products
February 27 2013
    Dear Sir/Madam:    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration...
Electronic Submissions: BIO Comments on Providing Submissions in Electronic Format
February 19 2013
    The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the...
SMU: BIO Statement on Creating an Alternative Approval Pathway for Certain Drugs Intended to Address Unmet Medical Need
February 4 2013
  The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to provide...
BIO Principles on Patient Safety in the Substitution of Biologic Products
January 24 2013
Biologics are complex medicines manufactured from living organisms. Unlike traditional “small molecule” drugs, biologics are...
Statement in Opposition to North Dakota S. 2066
January 24 2013
The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology trade association. BIO represents more than 1,...
More Letters, Testimony & Comments →

Press Releases

Ken Lisaius Named BIO's Vice President of Communications
January 23 2013
Washington, D.C. (January 23, 2013) –  The Biotechnology Industry Organization (BIO) announced that Ken...
BIO Strongly Opposes RFS Waiver Requests in Comments to EPA
October 9 2012
Any waiver of the RFS would have little to no effect on corn prices, but would certainly harm biofuel producers and...
Release of FDA Guidance for Biosimilars Pathway Marks Important Step Forward, Says BIO
February 9 2012
Patient Safety Must Remain Top Priority Washington, D.C. (February 9, 2012) — Biotechnology Industry...
BIO Comments on New Initiatives to Grow Nation’s Bioeconomy
September 16 2011
Washington, D.C. (September 16, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim...
Synthetic Biology’s Potential for Commercial Innovation Should Be Supported, BIO Argues
September 1 2011
WASHINGTON, D.C.(Sept. 1, 2011) – Research and development in synthetic biology is an evolution of...
More Press Releases →